464元一针，国产带状疱疹疫苗三折卖

Core Viewpoint - The price of the domestic varicella-zoster virus vaccine has been significantly reduced, impacting the sales and revenue of the company involved, 百克生物 (Baike Bio) [3][4]. Company Summary - 百克生物's varicella-zoster virus vaccine price has been lowered from 1375 yuan per dose to 464 yuan per dose, approximately one-third of the previous price [3]. - The company is facing sales and inventory pressures, with a reported revenue of 190 million yuan in Q3 2025, a year-on-year decline of 53.5% due to returns and price reductions [4]. - The company disclosed that 230 million yuan in revenue was impacted by returns of the varicella-zoster virus vaccine, with an additional estimated 97.46 million yuan in returns expected due to near-expiry inventory [4]. Industry Summary - There are currently two varicella-zoster virus vaccines available in the domestic market: 百克生物's live attenuated vaccine and a recombinant vaccine developed by GSK and marketed by 智飞生物 (Zhifei Bio) [5]. - Price competition for varicella-zoster virus vaccines has emerged since March 2025, with significant discounts being offered due to lower-than-expected sales [5]. - The varicella-zoster virus is known for causing severe pain and is prevalent among individuals over 50 years old, with a notable percentage of patients experiencing postherpetic neuralgia, making vaccination an effective preventive measure [4].